Literature DB >> 8834017

Fas antigen expression in liver tissues of patients with chronic hepatitis B.

K Mochizuki1, N Hayashi, N Hiramatsu, K Katayama, Y Kawanishi, A Kasahara, H Fusamoto, T Kamada.   

Abstract

BACKGROUND: Hepatitis B virus-infected cells can be eliminated by the cytotoxic T cell-mediated immune reaction. Fas ligand, recently detected on the surface of cytotoxic T cell, is thought to induce cells to apoptosis by adhering to Fas antigen. AIMS/
METHODS: To evaluate the role of Fas antigen and apoptosis in chronic hepatitis B, we immunohistochemically studied Fas antigen and HBsAg expression in liver samples from patients with hepatitis B virus infection.
RESULTS: In samples from 56 HBV patients, Fas antigen was mainly expressed in the cytoplasm (partly at the membrane) of hepatocytes, and these positive cells were detected especially at the periportal region near "piecemeal necrosis". According to Knodell's HAI scoring system, the scores of periportal inflammation and necrosis (category I) and the scores of intralobular inflammation and necrosis (category II) were similarly higher in Fas antigen-positive cases than in Fas antigen-negative cases (p < 0.01), and there was a positive correlation between these scores and the degree of Fas antigen expression. In normal cases, Fas antigen was not detected. In patients with HBV infection, Fas antigen expression was closely correlated with the activity of the viral hepatitis. HBsAg was expressed by the majority of hepatocytes. However, Fas antigen was expressed by fewer hepatocytes than the number of HBsAg-positive cells.
CONCLUSIONS: These findings suggest that the expression of Fas antigen may not be triggered only by HBV infection, and immunological interaction may be needed for the expression and for apoptosis to occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834017     DOI: 10.1016/s0168-8278(96)80178-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis.

Authors:  M Tagashira; K Yamamoto; K Fujio; T Nagano; R Okamoto; N Ibuki; K Yabushita; S Matsumura; N Okano; T Tsuji
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

2.  Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection.

Authors:  J Ehrmann; D Galuszková; J Ehrmann; I Krc; V Jezdinská; B Vojtések; P G Murray; Z Koláo
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 3.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

4.  Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody.

Authors:  Jo L McPartland; Muna Ali Guzail; Charles H Kendall; James Howard Pringle
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

Review 5.  Apoptosis: a mechanism of acute and chronic liver injury.

Authors:  M E Guicciardi; G J Gores
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B.

Authors:  Gong-Ying Chen; Jian-Qin He; Guo-Cai Lu; Ming-Wei Li; Chen-Huai Xu; Wei-Wei Fan; Chen Zhou; Zhi Chen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

7.  Detection of soluble TRAIL in HBV infected patients and its clinical implications.

Authors:  Li-Hui Han; Wen-Sheng Sun; Chun-Hong Ma; Li-Ning Zhang; Su-Xia Liu; Qiu Zhang; Li-Fen Gao; You-Hai Chen
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

8.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

Review 9.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

Review 10.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.